Comment on Clinical Profile of Genetically Proven Huntington’s Disease Patients From Eastern India

We read with great interest in the manuscript by Hussain et al.\cite{1} about clinical profile of Huntington’s disease (HD) in India, and we would like to contribute with a still unpublished data, of an ongoing study of a Brazilian cohort, with very similar founds.

We evaluated 36 patients with a genetic diagnosis of HD in a tertiary hospital in southern Brazil, with the objective of assessing the symptoms of HD at the onset. Among the total number of patients evaluated, 52.77% were male, and the age of onset ranged from 21 to 76, with a mean of 44.99 ± 9.96 years old. Also, out of the total, 25 patients had chorea as the initial presentation, two presented as ataxia, one had Parkinsonism, two had tics, one had dystonia, three had psychiatric or behavioral changes, and two cognitive symptoms [Table 1].

In our study, the paternal transmission was also commoner, especially in the non-choreic group, but the rate of de novo mutation was low, with only two patients.

The genetic expansion cytosine-adenine-guanine (CAG) ranged from 29 to 56 (mean 42.92 ± 4.26). These data bring us another interesting finding, a 29 CAG expansion length patient. But, different from your article, this patient was not excluded, since there is growing evidence of patients with less than 35 CAG repeats presenting a classic phenotype of HD.\cite{2-5} For this reason, we understand that an update of the current guidelines for HD testing is on the way.

Also, a difference between our studies was that we only included patients older than 20 years, aiming not to include patients with Juvenile Huntington’s disease (JHD) phenotype, and try to reduce possible biases by analyzing phenotypes of a group in which it is known to have a higher incidence of atypical presentations.

Since the motor impairment and the cognitive and psychiatric changes are subtle, it is often difficult to state the exact point at which the disease starts its development. Still, it is very hard to correlate cognitive and psychiatric features to HD, but as Movement Disorder Society Task Force has described, nonmotor signs should be considered in the manifest HD diagnosis criteria, in addition to motor features.\cite{6}

Both the rate in this study and the rate reported by Hussain et al. of nonmotor presentation of HD are higher than have been reported by literature, but, however, there are few studies whose reported data are similar to these.\cite{7,8} Most studies were focused on motor symptoms, even choreic or non-choreic. In this study, non-choreic presentations were also higher than previously reported studies.\cite{9,10}

In fact, all of these represent greater acceptance of nonmotor symptoms as a form of manifestation of HD, and it is reasonable to suppose that when cognitive, psychiatric and behavioral aspects are assessed together with motor signs, it may result in a slightly earlier diagnosis of HD; this is how important the data is.

As in India, there are no epidemiological studies regarding HD in Latin America, and studies capable of grouping so much information about the disease are even more important. In this way, recognizing atypical manifestations in HD is of paramount importance to prevent misdiagnosis, reason why we congratulate the authors on their research efforts in performing this study.

**Availability of data and materials**
All data generated or analyzed during this study are included in this published article.

**Ethics approval and consent to participate**
The study was approved at the ethics committee by number: CAAE 67130217.1.1001.0096. Written informed consent for participating in this study was obtained from all patients.

**Financial support and sponsorship**
Nil.

**Conflicts of interest**
There are no conflicts of interest.

**Table 1: Comparison of patient characteristics based on the initial clinical manifestation**

|                      | Total (n=36) | Initial clinical manifestation |                      |                      |                      |                      |
|----------------------|-------------|--------------------------------|----------------------|----------------------|----------------------|----------------------|
|                      |             | Chorea (n=25)                  | Other movement disorder (n=6) | Psychiatric (n=3)    | Cognitive (n=2)      |                      |
| Gender (M/F)         | 19/17       | 16/9                           | 3/3                  | 1/2                  | 0/2                  |                      |
| Age of first manifestation | 42 (21-76)  | 46 (21-76)                     | 44 (35-66)           | 40 (31-67)           | 43 (36-50)           |                      |
| Inheritance (P/M)    | 20/14       | 10/14                          | 4/1                  | 2/1                  | 2/0                  |                      |
| Repeat length        | 40 (29-56)  | 42 (29-56)                     | 44 (40-45)           | 39 (36-44)           | 41 (39-44)           |                      |

**Gustavo L. Franklin, Carlos Henrique Camargo, Alex T. Meira, Hélio A. G. Teive**
Letters to the Editor

Movement Disorders Unit, Neurology Service, Internal Medicine Department, HC, Federal University of Paraná, Curitiba/PR, Brazil

Address for correspondence: Dr. Gustavo L. Franklin, Rua General Carneiro 1103/102, Centro, Curitiba, PR, Brazil. E-mail: gustavolf_88@hotmail.com

REFERENCES

1. Hussain Z, Mukherjee A, Ganguly G, Joardar A, Roy S, Guin DS, et al. Clinical profile of genetically proven Huntington’s disease patients from Eastern India. Ann Indian Acad Neurol 2020;23:195-200.
2. Kenney C, Powell S, Jankovic J, Autopsy-proven Huntington’s disease with 29 trinucleotide repeats. Mov Disord 2007;22:127-30.
3. Andrich J, Arning L, Wieczorek S, Kraus PH, Gold R, Saß C. Huntington’s disease as caused by 34 CAG repeats. Mov Disord 2008;23:879-81.
4. Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martinez-Descalls A, Calvo S, Gil-Polo C, et al. Clinical manifestations of intermediate allele carriers in Huntington disease. Neurology 2016;87:571-8.
5. Savitt D, Jankovic J. Clinical phenotype in carriers of intermediate alleles in the Huntington gene. J Neurol Sci 2019;42:57-61.
6. Ross CA, Reilmann R, Cardoso F, McCusker EA, Testa CM, Stout J, et al. Movement disorder society task force viewpoint: Huntington’s disease diagnostic categories. Mov Disord Clin Pract 2019;6:541-6.
7. Hahn-Barma V, Deweer B, Durr A, Dode C, Feingold J, Pillon B, et al. Are cognitive changes the first symptoms of Huntington’s disease? A study of gene carriers. J Neurol Neurosurg Psychiatry 1998;64:172-7.
8. Paulsen JS, Miller AC, Hayes T, Shaw E. Cognitive and behavioral changes in Huntington disease before diagnosis. Handb Clin Neurol 2017;144:69-91.
9. Squitieri F, Berardelli A, Nargi E, Castellotti B, Mariotti C, Cannella M, et al. Atypical movement disorders in the early stages of Huntington’s disease: Clinical and genetic analysis. Clin Genet 2000;58: 50-6.
10. Becker N, Munhoz RP, Raskin S, Werneck LC, Teive HA. Non-choric movement disorders as initial manifestations of Huntington’s disease. Arq Neuropsiquiatr 2007;65:402-5.

Submitted: 16-Mar-2020 Accepted: 17-Mar-2020 Published: 24-Jun-2020

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

DOI: 10.4103/aian.182_20